Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia

Jonathan Feld, Shyamala C. Navada, Lewis R. Silverman

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Myelodysplastic syndromes (MDS) encompass a clinically heterogenous group of diseases defined by a clonal bone marrow failure state. Patients with lower-risk MDS primarily suffer from the consequences of anemia, with a subset having increased risks of bleeding and infection. There are few good therapeutic options for this patient population, as patients are dependent on cytokine support to improve hematopoiesis. Our review will discuss luspatercept, a transforming growth factor (TGF)-Beta ligand trap, the first new Food & Drug Administration (FDA)-approved treatment in MDS in over a decade. We will explore the different TGF-Beta ligand traps that have been developed for a number of diseases, with a focus on myeloid malignancies.

Original languageEnglish
Article number106430
JournalLeukemia Research
StatePublished - Oct 2020


  • Anemia
  • Luspatercept
  • Myelodysplastic syndromes
  • Sotatercept
  • TGF-Beta


Dive into the research topics of 'Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia'. Together they form a unique fingerprint.

Cite this